Get the Stockscreener App
3.97
1.24%
-0.05
Pre-market:
3.80
-0.17
-4.28%
Lantern Pharma Inc stock is traded at $3.97, with a volume of 86,674.
It is down -1.24% in the last 24 hours and up +6.15% over the past month.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
See More
Previous Close:
$4.02
Open:
$4.07
24h Volume:
86,674
Relative Volume:
0.13
Market Cap:
$50.65M
Revenue:
-
Net Income/Loss:
$-15.91M
P/E Ratio:
-2.7474
EPS:
-1.445
Net Cash Flow:
$-15.07M
1W Performance:
+8.17%
1M Performance:
+6.15%
6M Performance:
+27.65%
1Y Performance:
+24.84%
1-Day Range:
$3.90
$4.1801
1-Week Range:
$3.602
$4.34
52-Week Range:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.97 | 53.21M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance - The National Law Review
LTRN Forecast — Price Target — Prediction for 2027 - TradingView
Lantern Pharma, Inc. Actuals & Estimates (BOATS:LTRN) - TradingView
LTRN Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseConsensus Beat Rate - dars.gov.et
[EFFECT] Lantern Pharma Inc. SEC Filing - Stock Titan
Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lantern Pharma Inc (LTRN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lantern Pharma Inc (LTRN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lantern Pharma Inc (LTRN) Institutional Confidence - TradingKey
Lantern Pharma Inc (LTRN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma (LTRN) Faces Pressure: Shares Dip 4.67% as Technical Support at $3.69 LoomsContinuation Pattern Picks - newsline.com
LTRN Q1 2026 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress Remains KeyEarnings Surprise Score - newsline.com
Lantern Pharma (LTRN) Falls 4.7% as Biotech Stock Tests Key Support ZoneDividend Growth Stocks - newsline.com
Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk - Stock Titan
Lantern Pharma (LTRN) Extends Decline: Key Support Levels in Focus After 5.28% DropRisk Parity Rebalance - newsline.com
Lantern Pharma stock jumps on lung cancer trial survival data By Investing.com - Investing.com India
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - BioSpace
Lantern Pharma (LTRN) Shares Promising Phase 2 Trial Results - GuruFocus
Lantern Pharma stock jumps on lung cancer trial survival data - Investing.com
Lantern Pharma reports trial data for lung cancer treatment - Investing.com
Lantern Pharma reports trial data for lung cancer treatment By Investing.com - Investing.com Nigeria
Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer - TradingView
Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress - TipRanks
Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K - Stock Titan
Lantern Pharma Edges Higher: LTRN Holds Above Support After 2.57% GainCall Spread Alert - newsline.com
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma Inc. (LTRN) Gains 5.74% as Shares Test Key ResistanceEase of Movement - newsline.com
LTRN Q1 2026 Earnings: Narrowed Loss Per Share Beats Estimates as Pipeline Progress ContinuesEPS Growth Report - newsline.com
Lantern Pharma Announces $9.25 Million Registered Direct Offering - geneonline.com
LTRNLantern Pharma Inc Stock Price and Quote - Finviz
LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript - AOL.com
Lantern Pharma receives FDA clearance for trial amendments - Investing.com UK
Lantern Pharma receives FDA clearance for trial amendments By Investing.com - Investing.com South Africa
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - BioSpace
Lantern Pharma (LTRN) Receives FDA Support for Phase 2 Trial - GuruFocus
Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC - TradingView
About Us - FinancialContent
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Rev - GuruFocus
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):